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Abstract. Background: Genetic alterations occurring in lung
cancer are the basis for defining molecular subtypes and
essential for targeted therapies. Exhaled breath condensate
(EBC) is a form of non-invasive sample that, amongst
components, contains DNA from pulmonary tissue. Next-
generation sequencing (NGS) was herein used to analyze
mutations in EBC from patients with lung cancer. Materials
and Methods: EBC was collected from 26 patients with cancer
and 20 healthy controls. Amplicon-based sequencing using Ion
Ampliseq Colon and Lung Cancer gene panel v2 was applied.
Results: The sequencing was successful in 17 patients and 20
controls. EBC from patients revealed 39 hotspot mutations
occurring in: adenomatous polyposis coli (APC), v-raf murine
sarcoma viral oncogene homolog B (BRAF), discoidin domain
receptor tyrosine kinase 2 (DDR2), epidermal growth factor
receptor (EGFR), erb-b2 receptor tyrosine kinase 4 (ERBB4),
F-box and WD repeat domain containing 7 (FBXW7),
fibroblast growth factor receptor 1 (FGFR1), FGFR3
(fibroblast growth factor receptor 3), Kirsten rat sarcoma viral
oncogene homolog (KRAS), mitogen-activated protein kinase
kinase 1 (MAP2K1), met proto-oncogene (MET),
neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS),
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha (PIK3CA), phosphatase and tensin homolog
(PTEN), ret proto-oncogene (RET), SMAD family member 4
(SMAD4), serine/threonine kinase 11 (STK11), and tumor
protein p53 (TP53) genes. EBC from controls revealed 35
hotspot mutations. The average mutant allele fraction was
higher in patients than controls. Conclusion: NGS can identify
mutations in EBCs from patients with lung cancer. This could
provide a promising non-invasive method for the assessment
of gene mutations in lung cancer. 
Lung cancer is one of the most common malignancies
worldwide. Lung cancer has a poor prognosis and a long-
term survival rate that has not improved in the past 20
years (1). One reason for the poor tumor course and
outcome is the very late phase at which the malignancy is
diagnosed. At this phase, tumoral molecular changes lead
to resistance to multiple forms of treatment (2-5). Sufficient
tumor tissue biopsies are essential for making appropriate
diagnostic and therapeutic decisions during the course of
the disease. However, such biopsies are not always easily
obtained. Recently, free circulating DNA has been
investigated as a non-invasive method for the detection of
numerous genetic alterations associated with malignancy
and, thus, offers an alternative source of material for early
cancer diagnosis (6-9). 
Amongst other components, exhaled breath condensate
(EBC) contains DNA that seemingly originates from the
tumorous tissue in patients with lung carcinoma (10). Gene
mutations occurring at tumor protein p53 (TP53), Kirsten
rat sarcoma viral oncogene homolog (KRAS), epidermal
growth factor receptor (EGFR), and cyclin-dependent kinase
inhibitor 2A (CDKN2A) have been studied in EBC from
patients with different lung malignancies (11-14). We
recently demonstrated that next-generation sequencing
(NGS) can be used to study mutations in EBC from healthy
individuals (15). In the present study, we investigated the
applicability of EBC in patients with cancer. 
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Materials and Methods
Patients and controls. EBC samples were collected from 26 patients
with different lung neoplasms. We included any type of patient with
lung neoplasms who were physically fit to give 15 minutes
breathing and gave their consent. Seventeen patients had non-small
cell lung carcinoma (NSCLC) (eleven adenocarcinoma and six
squamous cell carcinoma), six had small cell lung carcinoma, two
had pleural mesothelioma, and one patient had a suspected
malignancy but did not have histopathological diagnosis (Table I).
EBC samples from eight patients were collected during or after
treatment (either chemotherapy, radiotherapy, or surgery). EBC from
the remaining 18 patients was collected before any specific cancer
treatment (Table II). Patients were diagnosed and treated at Helsinki
University Hospital. For controls, EBC was collected from 20
healthy individuals including healthy smokers, ex-smokers, and
non-smokers, and excluding those with pulmonary infections e.g.
common flu. Detailed information and results from controls were
reported previously (15). In brief, 10 healthy females (aged 25-56
years) and 10 healthy males (aged 25-68 years) were studied. 
The study was approved by the Hospital and Uusimaa (HUS)
Ethical Review Board (ethical permission number
253/13/03/01/2015). Written informed consent was obtained from
all patients and controls. 
EBC sample collection. Each patient provided an EBC sample by
breathing through an ECoScreen® (Eric Jaeger, Würzburg,
Germany) for 15 minutes. Mean breath volume and breathing
frequency were checked every 5 minutes until the end of the
collection procedure. Collected EBC samples were transported
immediately on ice to the laboratory. Samples were transferred into
2-ml tubes. The volume of EBC was measured for each sample and
then samples were stored at −70˚C.
DNA extraction. DNA was extracted from the whole EBC sample
using QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. The kit uses
RNA carrier and a vacuum for fast and efficient processing of DNA
from the whole sample (1-3 ml). DNA was measured using a
Qubit® 2.0 Fluorometer and Qubit® dsDNA HS Assay kit (Thermo
Fisher Scientific, Waltham, MA, USA).
NGS: Preparation of libraries. Ten nanograms of EBC DNA were
used for preparing amplicon libraries using Ion AmpliSeq™ Library
kit 2.0 (Thermo Fisher Scientific) according to the manufacturer’s
instructions. In order to amplify the template, Ion Ampliseq Colon
and Lung Cancer panel v2 (Thermo Fisher Scientific) was used. The
panel consisted of a primer pool of 92 amplicons covering 504
hotspot mutations in 22 genes frequently mutated in lung cancer. The
genes included in this panel are AKT serine/threonine kinase 1
(AKT1), ALK receptor tyrosine kinase (ALK), v-raf murine sarcoma
viral oncogene homolog B (BRAF), catenin beta 1 (CTNNB1),
discoidin domain receptor tyrosine kinase 2 (DDR2), EGFR, erb-b2
receptor tyrosine kinase 2 (ERBB2), erb-b2 receptor tyrosine kinase
4 (ERBB4), F-box and WD repeat domain containing 7 (FBXW7),
fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, KRAS,
mitogen-activated protein kinase kinase 1 (MAP2K1), met proto-
oncogene (MET), (Notch homolog 1, translocation-associated
(Drosophila) (NOTCH1), neuroblastoma RAS viral (v-ras) oncogene
homolog (NRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog
(PTEN), SMAD family member 4 (SMAD4), serine/threonine kinase
11 (STK11), and TP53. Only two samples from mesothelioma patients
were amplified by using the Ion AmpliSeq Cancer Hotspot Panel v2
(Life Technologies, California, USA). This panel consisted of primer
pool for 207 amplicons covering 2800 mutational hotspot regions in
50 genes, including ret proto-oncogene (RET) mutations. The
amplified libraries were purified using Agencourt AMPure XP beads
(Beckman Coulter Genomics, High Wycombe, UK). Library
concentrations were measured using Qubit® dsDNA HS Assay kit and
Qubit® 2.0 Fluorometer (Thermo Fisher Scientific). The libraries
were stored at −20˚C until the sequencing step was performed.
Template preparation and sequencing. The purified libraries were
diluted to 100 pM and subsequently amplified on Ion SphereTM
particles (Life Technologies). The templates were prepared and
enriched using the Ion OneTouch™ 2 System (Life Technologies),
an automated emulsion polymerase chain reaction system.
Sequencing was performed on the Ion Personal Genome Machine
System (PGM™; Life Technologies) using Ion 316™ chips and Ion
PGM™ Sequencing Hi-Q view kit v2.
NGS data analysis. Torrent Suite Software v.5.2.2 (Life
Technologies) was used to assess run performance and data analysis.
The Integrative Genomics Viewer (IGV v 2.4; Broad Institute,
Cambridge, MA, USA) was used for visual inspection of the aligned
reads. The Variant Caller plug-in (v5.2) was used for variant calling.
The same cutoff score as that used in our healthy control study was
applied, with a threshold for quality score ≥20 and for mutant allele
fraction ≥3% (15). This NGS 3% allele fraction cutoff was tested
previously for EGFR mutations in patients with lung cancer when
compared with a clinically approved real-time polymerase chain
reaction assay (16). Only single nucleotide variants resulting in a
non-synonymous amino acid change, a premature stop codon, and
indels resulting in either a frameshift or insertion or deletion of
amino acids were selected. All single nucleotide variants were
analyzed for previously reported hotspot mutations [somatic
mutations reported in the Catalogue of Somatic Mutations in Cancer
(COSMIC) database] and novel variations such as new mutations
detected by NGS, but not reported in either COSMIC
(https://cancer.sanger.ac.uk/cosmic) or dbSNP (build 151) databases
(https://www.ncbi.nlm.nih.gov/projects/SNP/).
Statistical analysis. Data were analyzed using IBM SPSS advanced
statistics version 24 (IBM, Armonk, NY, USA). Comparison
between the median EBC DNA concentration between two groups
was performed using the Mann–Whitney test (non-parametric t-test).
Independent samples t-test was used to compare significant
differences in the number of detected mutations between ‘before
treatment’ and the ’during/after treatment’ groups. All tests were
two-sided and p-values of 0.05 or less were considered statistically
significant. 
Results
Success rate. DNA was successfully isolated from all 26
patients; NGS was successful in 17 patients. Nine EBC
samples failed to amplify during sequencing (Table I). In the
previously studied healthy controls, DNA was successfully
isolated and sequenced in all 20 participants (15). 
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Hotspot mutations in EBC from patients and controls. For
both controls and patients, the same criteria for cutoff were
set and mutations with quality ≥20 and allelic frequency
≥3% were considered to be true mutations. By applying
these parameters to patient EBC samples, a total of 39
hotspot mutations that were previously reported as somatic
mutations in the COSMIC database and 98 novel mutations
(i.e. not previously reported) were identified. The most
frequent hotspot mutations occurred in the following genes:
TP53 (n=6), SMAD4 (n=6), PIK3CA (n=4), KRAS (n=3),
BRAF (n=2), ERBB4 (n=2), FBXW7 (n=2), MAP2K1 (n=2),
PTEN (n=2), STK11 (n=2), APC (n=1), DDR2 (n=1), EGFR
(n=1), FGFR1 (n=1), FGFR3 (n=1), MET (n=1), NRAS
(n=1), and RET (n=1). 
A total of 35 hotspot variants and 106 novel mutations
were detected at an allelic frequency ≥3% in EBC from
healthy controls, with hotspot mutations occurring at the
following genes: TP53 (11), KRAS (4), NRAS (3), SMAD4
(3), CTNNB1 (2), MET (2), PTEN (2), BRAF (1), DDR2 (1),
EGFR (1), ERBB2 (1), FBXW7 (1), FGFR3 (1), NOTCH1
(1), and PIK3CA (1) (15). Detailed information on all
hotspot mutations detected in both patients and controls,
along with corresponding mutant allele fraction and quality
score, are shown in Table III.
Mutations in corresponding tumor tissue. Out of the 17
successfully sequenced patient EBC samples, NGS reports
for tumor tissue from routine clinical diagnostics were
available for only four patients with adenocarcinomas (Table
IV). Tissue NGS in clinical diagnostic laboratory was
performed on Ion Torrent PGM using in-house cancer gene
panel 1, which included the following genes: EGFR, KIT,
KRAS, MET, NRAS, platelet-derived growth factor receptor
A (PDGFRA), PIK3CA (all exons), and BRAF (exons 11-15).
For patient EP-8, tumor DNA revealed mutations in KRAS
exon 3 (c.183A>C) and PDGFRA exon 4 (c.423G>T).
PDGFRA was not included in our patient panel; the KRAS
mutation was however not identified in EBC sequencing
results. In the tumor DNA of patient EP-16, a mutation in
MET exon 14 (c.3028+ 3del) was observed, which in our
analysis was outside of the amplicon region and was not
studied. In the other two patients with KRAS exon 2 (c.35
G>A) mutations in their tumor specimens, no corresponding
mutations were seen in their EBC samples (Table IV). 
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Table I. Summary of exhaled breath condensate samples collected and sequenced.
Category                                          Total samples                 Successful DNA                Successful                       Hotspot                     All mutations 
                                                            collected                           extraction                     sequencing                  mutation only              (hotspot + novel)
Patients                                                     26                                         26                                 17                                   14                                    17
NSCLC (AC)                                           11                                         11                                   6                                     5                                      6
NSCLC (SCC)                                           6                                           6                                   5                                     3                                      5
SCLC                                                         6                                           6                                   5                                     5                                      5
Mesothelioma                                            2                                           2                                   1                                     1                                      1
Suspected lung cancer†                             1                                           1                                   0                                     0                                      0
Healthy controls‡                                     20                                         20                                 20                                   15                                    18
NSCLC: Non-small cell lung carcinoma; AC: adenocarcinoma; SCC: squamous cell carcinoma; SCLC: small cell lung carcinoma. †No biopsy
confirmation. ‡See reference (15). 
Table II. Sample collection, sequencing, and detected mutations according to treatment status for all patients.
                                                                        Total samples collected                                         Successfully sequenced (number of detected mutations)
Category                                     Before treatment                    During/after treatment                     Before treatment                   During/after treatment
NSCLC (AC)                                          7                                                  4                                               4 (23)                                           2 (7)
NSCLC (SCC)                                        5                                                  1                                               5 (55)                                           0 (0)
SCLC                                                       4                                                  2                                               3 (27)                                           2 (14)
Mesothelioma                                         1                                                  1                                               0 (0)                                             1 (10)
Suspected malignancy                           1                                                  0                                               0 (0)                                             0 (0)
Total                                                        18                                                 8                                             12 (105)                                         5 (31)
NSCLC: Non-small cell lung carcinoma; AC: adenocarcinoma; SCC: squamous cell carcinoma; SCLC: small cell lung carcinoma. 
Mutation in relation to treatment status. EBC samples from
eight patients were collected during or after treatment
(chemotherapy, radiotherapy, or surgery); five out of these
eight samples were successfully sequenced. The number of
mutations detected in EBC samples was lower in these
treated patients compared to the non-treated patients.
However, this difference was not statistically significant
(p=0.83) (Table II). 
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Table III. Mutant allele fraction (MAF) and quality score of hotspot mutations detected in patients and controls.
Gene symbol                                                                                                                            Patients                                                  Controls
                                                            Gene name                                            Mutation      MAF (%)     Quality        Mutation       MAF (%)     Quality
APC                                       Adenomatous polyposis coli                             p.A1582P           99             1825               ND                NA              NA
BRAF                    V-raf murine sarcoma viral oncogene homolog B             p.Q461*             19              671            p.K601E             12               134
                                                                                                                            p.I457T              7               117                                                             
CTNNB1                                           Catenin beta 1                                              ND                NA             NA             p.T41A               4                 36
                                                                                                                                                                                          p.D32Y              11                99
DDR2                       Discoidin domain receptor tyrosine kinase 2                p.M629V             6               148            p.R105C             17               296
EGFR                                Epidermal growth factor receptor                          p.K708R             3                22            p.D761N             12               320
ERBB2                              Erb-B2 receptor tyrosine kinase 2                              ND                NA             NA           p.V773M            49              5897
ERBB4                              Erb-B2 receptor tyrosine kinase 4                          p.G237S              6                28                 ND                NA              NA
                                                                                                                           p.R232*            100            1914                                                            
FBXW7                      F-Box and WD repeat domain containing 7                 p.G391D            18               57             p.R278*             19              2123
                                                                                                                           p.R479*             13              246                                                             
FGFR1                             Fibroblast growth factor receptor 1                         p.P150S             38              496                ND                NA              NA
FGFR3                             Fibroblast growth factor receptor 3                        p.A634T            10              278           p.H274Y              7                298
KRAS                        Kirsten rat sarcoma viral oncogene homolog                 p.G13D             17              393            p.G12V               4                 27
                                                                                                                            p.D57N             12              374            p.D30Y               5                 44
                                                                                                                           p.K117R             6               133            p.T20M               4                 24
                                                                                                                                                                                          p.A11V               6                 33
MAP2K1                    Mitogen-activated protein kinase kinase 1                    p.R49C             18              588                ND                NA              NA
                                                                                                                            p.F53L               8                39                                                              
MET                                             Met proto-oncogene                                     p.N375S             41              439            p.R359L              6                192
                                                                                                                                                                                          p.S349G              7                 50
NOTCH1        Notch homolog 1, translocation-associated (Drosophila)            ND                NA             NA        p.V1578delV          4                 76
NRAS                 Neuroblastoma RAS viral (v-ras) oncogene homolog           p.V45A             12              210            p.D54G               5                 23
                                                                                                                                                                                           p.A11T               5                 24
                                                                                                                                                                                           p.G60E              25               682
PIK3CA                         Phosphatidylinositol-4,5-bisphosphate                     p.H1047Y           92             3492         p.M1043V           18               513
                                           3-kinase catalytic subunit alpha                           p.P421L            100             239                                                             
                                                                                                                           p.R537Q             6                59                                                              
                                                                                                                          p.G1049A           45             7095                                                            
PTEN                                 Phosphatase and tensin homolog                           p.321 fs             12              180            p.F258L              9                496
                                                                                                                           p.Y315H             3                42              p.L57S             100             1677
RET                                              RET proto-oncogene                                    p.C609V            96              711                ND                NA              NA
SMAD4                                    SMAD Family Member 4                                p.R497H            26             2003           p.S171L              4                 21
                                                                                                                            p.509 fs              7               173            p.F408S             10               144
                                                                                                                           p.H528R             6                63             p.A452T             56              2322
                                                                                                                           p.S191L             20              813                                                             
                                                                                                                           p.G352E            16              779                                                             
                                                                                                                          p.W509R             5                80                                                              
STK11                                      Serine/threonine kinase 11                               p.W332*            13              951                ND                NA              NA
                                                                                                                            p.E33K             21              649                                                             
TP53                                              Tumor protein p53                                      p.M246I             39             2106           p.G112S             27              1191
                                                                                                                           p.A353T            34              280            p.I251T               4                 20
                                                                                                                           p.H214Y            15              448             p.P72R               5               2639
                                                                                                                           p.R196P              9               249            p.S166P             11               763
                                                                                                                           p.G154S             27             1161           p.Q104*             20               354
                                                                                                                           p.P219L             13             1066           p.Y163*             11               202
                                                                                                                                                                                          p.F134L              6                 23
                                                                                                                                                                                          p.R337C             27              1407
                                                                                                                                                                                         p.N345D             24              1199
                                                                                                                                                                                          p.M169I              9                496
                                                                                                                                                                                          p.S269N              7                111
ND: Not detected; NA: not applicable. 
Discussion
In this study, we showed, to our knowledge for the first time,
that NGS can be adopted for analysis of EBC specimens
from patients with different lung malignancies. 
In our previous study, we optimized the application of
NGS to EBC from healthy individuals with a median DNA
concentration of 2,240 ng/ml (15). In the current study, we
applied the same methodological techniques to EBC from
patients with lung cancer to identify driver gene mutations.
The success rate in patients was 65.4%; nine samples did not
have sufficient sequencing reads even after repeating the
sequencing step. The common element between these
samples was a low DNA library concentration. Accordingly,
we examined DNA concentration as a possible cause for
failed amplification. The difference in median DNA
concentration between samples with successful sequencing
(1,560 ng/ml) and those with failed sequencing (1,380 ng/ml)
was statistically significant (p=0.037). When comparing
genes frequently mutated in both patients and controls (such
as TP53 and KRAS) for hotspot mutations, the average
mutant allele fraction was higher in patients than controls
(22.9% and 13.6% in TP53 and 11.4% and 4.3% in KRAS in
patients and controls, respectively). The presence of
mutations in healthy controls does not necessarily have a
clinical significance, but instead reflects a physiological
homeostatic process and removal of damaged DNA due to
continuous cellular turnover in pulmonary tissue (15).
Similar findings were highlighted in 2012 by Kordiak et al.,
who compared the ratio of mutant and wild-type KRAS in
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Table IV. Clinical characteristics of patients with successfully sequenced samples. 
                                                                                                                                                            Mutated genes
ID               Histopathology         Treatment status       Stage at                         Tissue*                                                         EBC**
                                                                                      diagnosis
EP-1            Mesothelioma           Chemotherapy             IV                                  NA                                   ABL1, APC, EGFR, FBXW7, FGFR3, 
                (epithelial subtype)                                                                                                                                  PIK3CA, RET, SMAD4, SMO 
EP-2             NSCLC (AC)          Before treatment          IVB                          No specific                               ERBB2, ERBB4, FGFR1, FGFR3, 
                                                                                                                              findings                                            KRAS, PIK3CA, PTEN
EP-3            NSCLC (SCC)         Before treatment          IIIB                                NA                                DDR2, ERBB4, FGFR3, KRAS, MAP2K1, 
                                                                                                                                                                         NRAS, PIK3CA, SMAD4, STK11, TP53
EP-4                   SCLC                Before treatment          IIIB                                NA                           DDR2, FGFR3, KRAS, MET, PIK3CA, SMAD4
EP-6            NSCLC (SCC)         Before treatment          IIIA                                NA                           ALK, DDR2, ERBB4, FBXW7, FGFR1, SMAD4
EP-7             NSCLC (AC)          Before treatment          IVA                          No specific                             ALK, BRAF, DDR2, EGFR, FGFR3, 
                                                                                                                              findings                                         MAP2K1, NRAS, PIK3CA
EP-8             NSCLC (AC)          Before treatment          IVB             KRAS exon 3 (c.183A>C),                                  ERBB4, FGFR3
                                                                                                            PDGFRA exon 4 (c.423G>T)
EP-9            NSCLC (SCC)         Before treatment          IIIA                                NA                                                  EGFR, MET, AKT1
EP-10           NSCLC (AC)            Chemotherapy            IVB               KRAS exon 2 (c.35G>A)                                    ERBB2, FGFR1
EP-16           NSCLC (AC)          Before treatment          IVA                        MET exon14                                             PIK3CA, ERBB2
                                                                                                                          c.3028+3del
EP-17           NSCLC (AC)     Surgery, chemotherapy,    IIIA               KRAS exon2 (c.35G>A)               NRAS, FBXW7, PTEN, MAP2K1, SMAD4
                                                        radiotherapy
EP-24                 SCLC                  Chemotherapy            IVA                                NA                                                 MET, SMAD4, TP53
EP-25                 SCLC                Before treatment          IVB                                NA                                        AKT1, DDR2, ERBB4, FGFR3, 
                                                                                                                                                                                  NRAS, PTEN, SMAD4, TP53
EP-26          NSCLC (SCC)         Before treatment          IIIB                                NA                                                            ERBB4
EP-27                 SCLC                  Chemotherapy            IIIA                                NA                                      FBXW7, FGFR3, MAP2K1, MET, 
                                                                                                                                                                                   NRAS, PTEN, STK11, TP53
EP-28                 SCLC                Before treatment          IVB                                NA                                        BRAF, FGFR1, FGFR3, KRAS, 
                                                                                                                                                                                         MET, SMAD4, TP53
EP-29          NSCLC (SCC)         Before treatment          IIIA                                NA                            ALK, BRAF, DDR2, ERBB4, FBXW7, FGFR1, 
                                                                                                                                                                              FGFR2, FGFR3, KRAS, PIK3CA, 
                                                                                                                                                                                 PTEN, SMAD4, STK11, TP53
NGS: Next-generation sequencing; NA: tissue sequencing not applicable; NSCLC: non-small cell lung carcinoma; AC: adenocarcinoma; SCC:
squamous cell carcinoma; SCLC: small cell lung carcinoma; SMO: smoothened, frizzled class receptor. *Gene panel for tissue sequencing included
only EGFR, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, and BRAF. **Gene panels for EBC sequencing included 22 genes (Ion Ampliseq Colon
and Lung Cancer panel v2) and 50 genes (Ion AmpliSeq Cancer Hotspot Panel v2). See Table III for other gene names. 
EBC from patients with lung cancer and healthy controls.
The authors revealed a significantly higher ratio of
mutant:wild-type KRAS in patients (0.20±0.03) than in
controls (0.028±0.032). They also compared the ratio of
mutant:wild-type KRAS between tissue tumors and normal
pulmonary parenchyma and found significantly higher values
in cancerous tissues (12). 
Testing for KRAS mutational status may have a predictive
value in different treatment protocols, as this mutation confers
resistance to a wide variety of therapeutic agents, including
chemotherapy and inhibitors of angiogenesis and EGFR (17).
Four patients with adenocarcinomas had NGS results from
tumor tissue acquired during routine clinical diagnostics. We
compared these results with the corresponding EBC
sequencing data. In patient EP-8, KRAS exon 3 mutation
(c.183A>C) was detected in the tissue specimen, but was not
observed in the patient’s EBC. Patients EP-10 and EP-17 had
a KRAS exon 2 (c.35G>A) mutation in their tissue specimens
collected at the time of diagnosis (6 months and 18 months
prior to EBC sampling, respectively) that were not detected
in EBC. However, the EBC samples from these patients were
collected when they had already undergone cancer treatment.
For patient EP-10, EBC was collected during chemotherapy
and VEGFR-inhibitor treatment. For patient EP 17, EBC was
collected after radical treatment (lobectomy with adjuvant
chemotherapy and radiotherapy). It not known whether the
absence of mutations in EBC is due to treatment effect or
other reasons. A previous reports showed a significant
decrease in the mutant:wild-type allelic fraction of KRAS in
EBC after tumor resection (12). 
Comparing the pattern of hotspot mutations in EBC
between patients and controls illustrated that some genes
were mutated only in patient EBC samples (APC, FGFR1,
RET, MAP2K1, and STK11). One of these mutations was
MAP2K1 F53L, which has been reported to be associated
with a distinct subset of lung adenocarcinoma and is a
possible target for mitogen-activated protein kinase inhibitors
(18). Mutations in BRAF, FBXW7, PIK3CA, and SMAD4
were found in both patients and controls but more frequently
in patients (Figure 1). PIK3CA gene mutation was found in
the patient group at codon 1047 (H1047Y), which is
commonly mutated in NSCLC and may mediate resistance
to anti-EGFR and other targeted therapies (19, 20). 
Although the relevance of the mutational patterns
observed in EBC is not yet clear, we feel that this should be
reported due to the limited number of such studies on EBC.
In addition, hotspot mutations in EBC categorized according
to histological tumor types are given in Table V. The
presence of hotspot mutations in apparently healthy
individuals has also been reported in other studies (21, 22).
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Figure 1. Pattern of hotspot mutations in exhaled breath condensate from patients and controls. See Table III for gene names. 
Accumulation of mutations in somatic cells is a major step
in the multistep process of tumorigenesis (23). There is also
a correlation between increased mutation rate and increased
lifetime incidence of lung cancer. It is believed that every
~30 mutations in the coding region are associated with a
0.2% increase of lifetime incidence of cancer in general (24).
In our study, the average number of hotspot mutations in
patient EBC samples (2.29) was higher than the average
from control EBC samples (1.75). However, this was not
statistically significant (p=0.292). Additionally, tissue NGS
was not applicable to 15 patients due to the widely accepted
clinical practice that only adenocarcinomas, and never
smokers/former light smokers with other lung cancer
histology are routinely tested. In real-life situations, there is
often insufficient tissue material for tumor molecular
profiling, which highlights the need for easily accessible
samples such as EBC for molecular analysis in such difficult
cases. Importantly, EBC might be able to replace the need
for tumor re-biopsies in following the disease course and
could facilitate detection of new resistance mutations during
treatment. EBC may also be an ideal sample for screening of
mutations and other genetic alterations in individuals at
substantial risk of lung cancer, such as smokers and persons
exposed to asbestos. 
Our study has limitations, as we only had NGS results
from corresponding tumor tissue for four patients to compare
mutations seen in EBC. Moreover, two of these patients had
undergone treatment since their tissue analysis, which makes
it difficult to draw any conclusion regarding the concordance
of results between EBC and tumor tissue. Further studies on
a larger number of patients and comparison of their tumor
and EBC mutation profile is required to assess the accuracy
of EBC mutation profiling for diagnostic applications. 
Conclusion 
In the present study, hotspot mutations were detectable in
EBC from patients with different types of lung malignancies.
The mutant allele fraction for hotspot mutations was higher
in EBC samples from patients than from healthy controls.
EBC may provide a helpful tool in cancer diagnostics and
molecular profiling. Genomic studies on EBC in lung cancer
are still at an early phase. Further investigations are required
to test the applicability of NGS for clinical use. 
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